James Flynn, MD
Cardiovascular Disease · Londonderry, NHNPI 1174584361
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,986 of the $9,011 with a category attached, or 66.4%. 20 manufacturers reported payments, led by Edwards Lifesciences at 35.4% of the total. Reporting peaked in 2019 at $2,287 and has fallen 63.6% since, to $833 in 2025.
Across 125 payments — averaging $72.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$3K
- Abbott$2K
- Medtronic$1K
- Abiomed$526
- Inari Medical, Inc.$463
- Boston Scientific$418
- plus $1K from 14 others
Across 24 payments — averaging $1573.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$38K
What the payments were for
- Travel & lodging$2,69830%
- Food & beverage$5,98666%
- Education$461%
- Other$2823%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 26 | $3,186 |
| Abbott | 26 | $1,841 |
| Medtronic(2 entities) | 22 | $1,089 |
| Abiomed | 5 | $526 |
| Inari Medical, Inc. | 7 | $463 |
| Boston Scientific | 4 | $418 |
| Stryker | 6 | $356 |
| Novartis | 6 | $221 |
| Endotronix, Inc. | 1 | $168 |
| Opsens Inc. | 7 | $156 |
| Shockwave Medical, Inc | 1 | $132 |
| Philips North America LLC | 1 | $87 |
| AstraZeneca | 3 | $78 |
| Johnson & Johnson | 2 | $70 |
| Novo Nordisk | 1 | $63 |
| Scpharmaceuticals Inc. | 1 | $38 |
| EKOS Corporation | 2 | $34 |
| Cardiovascular Systems Inc. | 1 | $31 |
| Siemens Medical Solutions USA, Inc. | 2 | $29 |
| Pfizer | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$1,326
- PASCAL$1,135
- Impella$466
- FLOWTRIEVER CATHETER, S$385
- CT THROMBECTOMY SYSTEM KIT$385
- CARDIOMEMS$299
- MitraClip$283
- PORTICO$282
- SAPIEN 3 Ultra RESILIA$278
- COREVALVE EVOLUT R$265
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$168
- FlowTriever$161
- Tendyne Mitral Valve System$158
- CardioMEMS HF System$150
- CoreValve Evolut$133
- Vascular Lithotripsy$132
- SYMPLICITY G3$121
- WATCHMAN FLX$118
- ENTRESTO$117
- AMPLATZER Occluders$113
How this compares
$9,011 in reported general payments places this provider in the 85th percentile of 112 cardiovascular disease providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 106 | $149,028 |
| FarxigaDapagliflozin Propanediol | 43 | $46,262 |
| XareltoRivaroxaban | 38 | $34,320 |
| JardianceEmpagliflozin | 12 | $16,378 |
| CrestorRosuvastatin Calcium | 12 | $3,266 |
| Metoprolol Succinate | 170 | $2,726 |
| Atorvastatin Calcium | 125 | $1,466 |
| Ezetimibe | 21 | $1,359 |
| Lisinopril | 94 | $654 |
| Amlodipine Besylate | 106 | $608 |
| ClopidogrelClopidogrel Bisulfate | 35 | $504 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 21 | $442 |
| Warfarin Sodium | 21 | $441 |
| Rosuvastatin Calcium | 41 | $414 |
| Losartan Potassium | 37 | $399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $25 | $149,028106 claims |
| AstraZenecaFarxiga, Crestor | $78 | $49,52955 claims |
| Johnson & JohnsonXarelto | $70 | $34,32038 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 112 cardiovascular disease providers in New Hampshire.
Other cardiovascular disease in Londonderry
- Fahad GilaniManchester$418K
- Stephan HeoManchester$116K
- Robert CapodilupoManchester$85K
- Kevin KwakuLebanon$79K
- Michael YoungLebanon$53K
- Jeanney LewManchester$36K
- Daniel PipilasDover$28K
- Peter DourdoufisPortsmouth$21K
- Merle MyersonLebanon$15K
- Ian GilchristLebanon$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.